Segui
Andrea Calcagno
Andrea Calcagno
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino
Email verificata su unito.it
Titolo
Citata da
Citata da
Anno
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19
S Sciascia, F Aprà, A Baffa, S Baldovino, D Boaro, R Boero, S Bonora, ...
Clin Exp Rheumatol 38 (3), 529-532, 2020
3732020
The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65–74 years and more than 75 years
G Guaraldi, A Malagoli, A Calcagno, C Mussi, BM Celesia, F Carli, ...
BMC geriatrics 18, 1-10, 2018
1582018
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era
E Cerrato, F D'Ascenzo, G Biondi-Zoccai, A Calcagno, S Frea, ...
European heart journal 34 (19), 1432-1436, 2013
1452013
Tuberculosis and COVID-19 co-infection: description of the global cohort
TB/COVID-19 Global Study Group
European Respiratory Journal 59 (3), 2022
1212022
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis
F D'Ascenzo, E Cerrato, A Calcagno, W Grossomarra, F Ballocca, ...
Atherosclerosis 240 (1), 197-204, 2015
1192015
Cardiovascular disease in HIV patients: from bench to bedside and backwards
E Cerrato, A Calcagno, F D'ascenzo, G Biondi-Zoccai, M Mancone, ...
Open heart 2 (1), e000174, 2015
1142015
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system
A Calcagno, G Di Perri, S Bonora
Clinical pharmacokinetics 53, 891-906, 2014
812014
Ultrasensitive assessment of residual HIV viraemia in HAART‐treated patients with persistently undetectable plasma HIV‐RNA: A cross‐sectional evaluation
S Bonora, E Nicastri, A Calcagno, D Gonzalez de Requena, G D'Ettorre, ...
Journal of medical virology 81 (3), 400-405, 2009
712009
Diagnostic SARS-CoV-2 cycle threshold value predicts disease severity, survival, and six-month sequelae in COVID-19 symptomatic patients
M Trunfio, F Venuti, F Alladio, BM Longo, E Burdino, F Cerutti, V Ghisetti, ...
Viruses 13 (2), 281, 2021
682021
Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control
A Calcagno, M Simiele, MC Alberione, M Bracchi, L Marinaro, S Ecclesia, ...
Clinical Infectious Diseases 60 (2), 311-317, 2015
652015
Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort
A Mondi, A Cozzi‐Lepri, A Tavelli, S Rusconi, F Vichi, ...
African Journal of Reproduction and Gynaecological Endoscopy 22 (1), 2019
632019
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function
A Calcagno, D Gonzalez De Requena, M Simiele, A D'Avolio, MC Tettoni, ...
Antimicrobial agents and chemotherapy 57 (4), 1840-1843, 2013
622013
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis
S Gili, W Grosso Marra, F D'Ascenzo, E Lonni, A Calcagno, M Cannillo, ...
European heart journal 37 (48), 3600-3609, 2016
612016
Co-infection with other respiratory pathogens in COVID-19 patients
A Calcagno, V Ghisetti, E Burdino, M Trunfio, T Allice, L Boglione, ...
Clinical Microbiology and Infection 27 (2), 297-298, 2021
592021
HIV infection and primary prevention of cardiovascular disease: lights and shadows in the HAART era
F Ballocca, S Gili, F D’Ascenzo, WG Marra, M Cannillo, A Calcagno, ...
Progress in cardiovascular diseases 58 (5), 565-576, 2016
582016
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T> C polymorphism
M Siccardi, A D'Avolio, S Nozza, M Simiele, L Baietto, FR Stefani, D Moss, ...
Pharmacogenetics and genomics 20 (12), 759-765, 2010
582010
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment
A D'Avolio, A Ciancio, M Siccardi, A Smedile, L Baietto, M Simiele, ...
Therapeutic drug monitoring 34 (2), 165-170, 2012
522012
Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients
A Calcagno, C Atzori, A Romito, D Vai, S Audagnotto, ML Stella, ...
Journal of neurovirology 22, 88-92, 2016
512016
Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study
S Nozza, A Malagoli, L Maia, A Calcagno, E Focà, G De Socio, S Piconi, ...
Journal of Antimicrobial Chemotherapy 72 (10), 2879-2886, 2017
492017
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?
I Motta, A Calcagno, S Bonora
Expert opinion on drug metabolism & toxicology 14 (1), 59-82, 2018
482018
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20